Avery Dennison, a prominent player in the biotech market, has been the subject of numerous estimates and ratings by analysts lately. Some opinions contend that the firm's shares remain undervalued by a substantial degree. Year-end results for 2024 reflect a triumphant year, with record revenues driven mainly by the materials division's spectacular growth. The
fourth-quarter results, in particular, beat expectations, underlined by an EPS growth of 26% in Q2. However, the market appeared unimpressed with the company's
quarterly dividend announcement and
2025 EPS outlook, causing the stock to reach a 52-week low. Yet, J.P. Morgan opts to remain bullish, predicting an imminent upward price correction. Further, the company has recently appointed
Danny Allouche as Interim CFO. Meanwhile, spark of interest has been registered by several institutionals increasing their stock positions. Estimates for EPS in Q1 have been lifted with persistent bullish ratings from Truist Financial and Raymond James, albeit a dip in shares by 5.3% due to sub-par earnings.
Avery Dennison Stocks AVY News Analytics from Wed, 20 Jun 2018 20:59:52 GMT to Fri, 28 Feb 2025 19:51:37 GMT -
Rating 2
- Innovation -2
- Information 8
- Rumor -6
